1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1247,
2000,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
2. |
Should antiarrhythmic drugs and ICDs be used together? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1247,
2000,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1247,
2000,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
4. |
Propentofylline worth it in Canada's AD population |
|
Inpharma Weekly,
Volume &NA;,
Issue 1247,
2000,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
5. |
Amfebutamone news from the 153rd Annual Meeting of the American Psychiatric Association |
|
Inpharma Weekly,
Volume &NA;,
Issue 1247,
2000,
Page 6-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
6. |
IFN-β cost effective for MS after all? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1247,
2000,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
7. |
Sublingual apomorphine: which dose in erectile dysfunction? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1247,
2000,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1247,
2000,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1247,
2000,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
10. |
Infliximab: a biological breakthrough in Crohn's disease therapy |
|
Inpharma Weekly,
Volume &NA;,
Issue 1247,
2000,
Page 11-12
Nicola Ryan,
Preview
|
|
摘要:
The last few years have seen the first real breakthrough in the treatment of Crohn's disease for many decades. Speaking at Digestive Disease Week 2000 [San Diego, US; May 2000], Dr Jonathon Terdiman from the University of California, San Francisco, US, said that'we are in the midst of a revolution in terms of our understanding of mucosal immunology, which has led to the advent of biological therapy for inflammatory bowel disease'.He continued by saying that increasing knowledge of this topic will allow for many new therapies over the next decade.'Infliximab was the first biological to market, but clearly it is not going to be the last',he concluded.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|